Type 1 diabetes (T1D) is a chronic disease characterized by the autoimmune destruction of insulin-producing β-cells in the pancreas. Replacement of β-cells by islet transplantation has proven to be successful in providing a functional cure for T1D. We previously showed that microencapsulation of allogeneic islets (allo-islets) or xenogeneic islets with CXCL12 promotes β-cell function, provides immune protection, and facilitates vascularization at the graft site in both small- and large-animal models of T1D. In addition, streptavidin-Fas ligand (SA-FasL) microgels induce immune acceptance of allo-islets through expansion of T regulatory cells (Tregs) in combination with short-term systemic immune suppression. This study evaluated a combination of these two complementary approaches for extending allo-islet graft survival in a mouse model of T1D through the codelivery of SA-CXCL12 or a protease-resistant variant of the chemokine (SA-prCXCL12) and SA-FasL within biotinylated microgels in an allogeneic-transplant setting. We demonstrated that microgels coated with SA-FasL and SA-prCXCL12, when cotransplanted with allo-islets, sustained long-term (6 months) diabetes reversal in streptozotocin-treated mice without any systemic immunosuppression more effectively than either agent alone. Our findings demonstrate in this murine model of diabetes that microgels delivering a combination of SA-prCXCL12 and SA-FasL induce long-term local immune protection of the allo-islet graft, enhance intragraft Treg recruitment, and improve graft vascularization while abrogating the need for any systemic immune suppression.
- Cotransplantation of allogeneic islets with microgels coated with streptavidin fused with Fas ligand and protease-resistant CXCL12 results in robust and sustained diabetes reversal for over 6 months in streptozotocin-induced diabetic mice and induces local immunomodulation, enhances Treg recruitment within the graft, and improves graft vascularization.
- This study addresses a critical challenge in cell transplantation, namely the need to develop technologies that enable local immunoprotection of the graft while eliminating the need for systemic immunosuppression.
- This combination microgel technology could offer a more favorable risk-benefit profile by reducing infection risks, organ toxicity, and tumorgenicity associated with the use of systemic immunosuppression.
- This novel combinatory immune modulatory approach is feasible and achieves anatomic site-specific immune protection while supporting long-term islet graft function without systemic immune suppression.

Leave a Reply